Sort   by:  
 Page size 
UnknownQuality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Not available
S-EPMC6804841 | biostudies-literature
UnknownTivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Not available
S-EPMC5569677 | biostudies-literature
UnknownPhase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Not available
S-EPMC10471185 | biostudies-literature
UnknownBiomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Not available
S-EPMC12459081 | biostudies-literature
UnknownCabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Not available
S-EPMC5024539 | biostudies-literature
UnknownNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Not available
S-EPMC5972549 | biostudies-literature
UnknownAbiraterone and increased survival in metastatic prostate cancer.
Not available
S-EPMC3471149 | biostudies-literature
UnknownLapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
Not available
S-EPMC8532036 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053 | biostudies-literature
Sort   by:  
 Page size